AdvisorShares Investments LLC cut its holdings in Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) by 24.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 882,488 shares of the company's stock after selling 288,381 shares during the period. AdvisorShares Investments LLC owned about 1.07% of Cardiol Therapeutics worth $1,130,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of CRDL. Jane Street Group LLC acquired a new stake in Cardiol Therapeutics during the third quarter worth about $29,000. Jones Financial Companies Lllp purchased a new position in Cardiol Therapeutics in the fourth quarter valued at approximately $25,000. Virtu Financial LLC acquired a new position in Cardiol Therapeutics during the fourth quarter valued at approximately $61,000. Atria Investments Inc acquired a new stake in shares of Cardiol Therapeutics in the fourth quarter worth $174,000. Finally, Lion Street Advisors LLC increased its holdings in Cardiol Therapeutics by 12.6% in the 4th quarter. Lion Street Advisors LLC now owns 307,666 shares of the company's stock valued at $396,000 after purchasing an additional 34,385 shares in the last quarter. Hedge funds and other institutional investors own 12.49% of the company's stock.
Cardiol Therapeutics Stock Performance
Shares of NASDAQ:CRDL traded up $0.02 during trading hours on Friday, hitting $1.14. The stock had a trading volume of 152,719 shares, compared to its average volume of 376,559. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.49 and a current ratio of 2.49. Cardiol Therapeutics Inc. has a 1-year low of $0.77 and a 1-year high of $3.12. The stock's fifty day simple moving average is $1.04 and its 200 day simple moving average is $1.34. The firm has a market capitalization of $94.17 million, a price-to-earnings ratio of -2.92 and a beta of 1.00.
Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. Sell-side analysts anticipate that Cardiol Therapeutics Inc. will post -0.33 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the company. RODMAN&RENSHAW upgraded Cardiol Therapeutics to a "strong-buy" rating in a report on Tuesday, January 28th. Rodman & Renshaw started coverage on shares of Cardiol Therapeutics in a research report on Tuesday, January 28th. They issued a "buy" rating and a $7.00 target price for the company. Finally, HC Wainwright reissued a "buy" rating and set a $9.00 price target on shares of Cardiol Therapeutics in a research report on Wednesday, April 16th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Cardiol Therapeutics currently has a consensus rating of "Buy" and an average price target of $8.40.
View Our Latest Analysis on CRDL
Cardiol Therapeutics Company Profile
(
Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Read More
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
